Head and Neck Pathology

, Volume 10, Issue 2, pp 119–124 | Cite as

Nevoid Basal Cell Carcinoma Syndrome (Gorlin Syndrome)

  • Scott C. Bresler
  • Bonnie L. Padwa
  • Scott R. Granter
Proceedings of the North American Society of Head and Neck Pathology Companion Meeting, March 13, 2016, Seattle, Washington

Abstract

Nevoid basal cell carcinoma syndrome, or basal cell nevus syndrome (Gorlin syndrome), is a rare autosomal dominantly inherited disorder that is characterized by development of basal cell carcinomas from a young age. Other distinguishing clinical features are seen in a majority of patients, and include keratocystic odontogenic tumors (formerly odontogenic keratocysts) as well as dyskeratotic palmar and plantar pitting. A range of skeletal and other developmental abnormalities are also often seen. The disorder is caused by defects in hedgehog signaling which result in constitutive pathway activity and tumor cell proliferation. As sporadic basal cell carcinomas also commonly harbor hedgehog pathway aberrations, therapeutic agents targeting key signaling constituents have been developed and tested against advanced sporadically occurring tumors or syndromic disease, leading in 2013 to FDA approval of the first hedgehog pathway-targeted small molecule, vismodegib. The elucidation of the molecular pathogenesis of nevoid basal cell carcinoma syndrome has resulted in further understanding of the most common human malignancy.

Keywords

Nevoid basal cell carcinoma syndrome Basal cell nevus syndrome Gorlin syndrome Keratocystic odontogenic tumor PTCH1 SMO SUFU Vismodegib 

References

  1. 1.
    Howell B, Caro M. The basal-cell nevus. Arch Dermatol. 1959;79:67–80.CrossRefGoogle Scholar
  2. 2.
    Gorlin R, Goltz R. Multiple nevoid basal-cell epithelioma, jaw cysts and bifid rib. A syndrome. N Engl J Med. 1960;5:908–12.CrossRefGoogle Scholar
  3. 3.
    Kimonis VE, Goldstein AM, Pastakia B, Yang ML, Kase R, Digiovanna JJ, et al. Clinical manifestations in 105 persons with nevoid basal cell carcinoma syndrome. Am J Med Genet. 1997;69:299–308.CrossRefPubMedGoogle Scholar
  4. 4.
    Anderson DE, Taylor WB, Falls HF, Davidson RT. The nevoid basal cell carcinoma syndrome. Am J Hum Genet. 1967;19:12–22.PubMedPubMedCentralGoogle Scholar
  5. 5.
    Shanley S, Ratcliffe J, Hockey A, Haan E, Oley C, Ravine D, et al. Nevoid basal cell carcinoma syndrome: review of 118 affected individuals. Am J Med Genet. 1994;50:282–90.CrossRefPubMedGoogle Scholar
  6. 6.
    Johnson RL, Rothman AL, Xie J, Goodrich LV, Bare JW, Bonifas JM, et al. Human homolog of patched, a candidate gene for the basal cell nevus syndrome. Science. 1996;272:1668–71.CrossRefPubMedGoogle Scholar
  7. 7.
    Klein RD, Dykas DJ, Bale AE. Clinical testing for the nevoid basal cell carcinoma syndrome in a DNA diagnostic laboratory. Genet Med. 2005;7:611–9.CrossRefPubMedGoogle Scholar
  8. 8.
    Gailani MR, Ståhle-Bäckdahl M, Leffell DJ, Glynn M, Zaphiropoulos PG, Pressman C, et al. The role of the human homologue of Drosophila patched in sporadic basal cell carcinomas. Nat Genet. 1996;14:78–81.CrossRefPubMedGoogle Scholar
  9. 9.
    Gailani MR, Bale SJ, Leffell DJ, DiGiovanna JJ, Peck GL, Poliak S, et al. Developmental defects in Gorlin syndrome related to a putative tumor suppressor gene on chromosome 9. Cell. 1992;69:111–7.CrossRefPubMedGoogle Scholar
  10. 10.
    Hahn H, Wicking C, Zaphiropoulous PG, Gailani MR, Shanley S, Chidambaram A, et al. Mutations of the human homolog of Drosophila patched in the nevoid basal cell carcinoma syndrome. Cell. 1996;85:841–51.CrossRefPubMedGoogle Scholar
  11. 11.
    Levanat S, Gorlin RJ, Fallet S, Johnson DR, Fantasia JE, Bale AE. A two hit model for developmental defects in Gorlin syndrome. Nat Genet. 1996;14:353–6.CrossRefGoogle Scholar
  12. 12.
    Atwood SX, Chang ALS, Oro AE. Hedgehog pathway inhibition and the race against tumor evolution. J Cell Biol. 2012;199:193–7.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Varjosalo M, Taipale J. Hedgehog: functions and mechanisms. Genes Dev. 2008;22:2454–72.CrossRefPubMedGoogle Scholar
  14. 14.
    Cherry AL, Finta C, Karlström M, Jin Q, Schwend T, Astorga-Wells J, et al. Structural basis of SUFU-GLI interaction in human Hedgehog signalling regulation. Acta Crystallogr Sect D Biol Crystallogr. 2013;69:2563–79.CrossRefGoogle Scholar
  15. 15.
    Soufir N, Gerard B, Portela M, Brice A, Liboutet M, Saiag P, et al. PTCH mutations and deletions in patients with typical nevoid basal cell carcinoma syndrome and in patients with a suspected genetic predisposition to basal cell carcinoma: a French study. Br J Cancer. 2006;95:548–53.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Smith MJ, Beetz C, Williams SG, Bhaskar SS, O’Sullivan J, Anderson B, et al. Germline mutations in SUFU cause Gorlin syndrome-associated childhood medulloblastoma and redefine the risk associated With PTCH1 mutations. J Clin Oncol. 2014;32:4155–61.CrossRefPubMedGoogle Scholar
  17. 17.
    Rogers HW, Weinstock MA, Harris AR, Hinckley MR, Feldman SR, Fleischer AB, et al. Incidence estimate of nonmelanoma skin cancer in the United States. Arch Dermatol. 2006;2010(146):283–7.Google Scholar
  18. 18.
    Guo YY, Zhang JY, Li XF, Luo HY, Chen F, Li TJ. PTCH1 Gene mutations in keratocystic odontogenic tumors: a study of 43 Chinese patients and a systematic review. PLoS One. 2013;8:1–9.Google Scholar
  19. 19.
    Pietsch T, Waha A, Koch A, Kraus J, Albrecht S, Tonn J, et al. Medulloblastomas of the desmoplastic variant carry mutations of the human homologue of Drosophila patched. Cancer Res. 1997;57:2085–8.PubMedGoogle Scholar
  20. 20.
    Epstein EH. Basal cell carcinomas: attack of the hedgehog. Nat Rev Cancer. 2008;8:743–54.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Reifenberger J, Wolter M, Knobbe CB, Köhler B, Schönicke A, Scharwächter C, et al. Somatic mutations in the PTCH, SMOH, SUFUH and TP53 genes in sporadic basal cell carcinomas. Br J Dermatol. 2005;152:43–51.CrossRefPubMedGoogle Scholar
  22. 22.
    Evans DG, Ladusans EJ, Rimmer S, Burnell LD, Thakker N, Farndon PA. Complications of the naevoid basal cell carcinoma syndrome: results of a population based study. J Med Genet. 1993;30:460–4.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Bree AF, Shah MR for the BCNS Colloquium Group. Consensus statement from the first international colloquium on basal cell nevus syndrome (BCNS). Am J Med Genet Part A. 2011;155:2091–7CrossRefGoogle Scholar
  24. 24.
    Parren LJMT, Frank J. Hereditary tumour syndromes featuring basal cell carcinomas. Br J Dermatol. 2011;165:30–4.CrossRefPubMedGoogle Scholar
  25. 25.
    Abuzahra F, Parren LJ, Frank J. Multiple familial and pigmented basal cell carcinomas in early childhood - Bazex-Dupre-Christol syndrome. J Eur Acad Dermatol Venereol. 2012;26:117–21.CrossRefPubMedGoogle Scholar
  26. 26.
    Parren LJMT, Abuzahra F, Wagenvoort T, Koene F, Van Steensel MAM, Steijlen PM, et al. Linkage refinement of Bazex-Dupré-Christol syndrome to an 11·4-Mb interval on chromosome Xq25-27.1. Br J Dermatol. 2011;165:201–3.CrossRefPubMedGoogle Scholar
  27. 27.
    Karagas MR, Zens MS, Li Z, Stukel TA, Perry AE, Gilbert-Diamond D, et al. Early-onset basal cell carcinoma and indoor tanning: a population-based study. Pediatrics. 2014;134:e4–12.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Woo S-B. Oral pathology: a comprehensive atlas and text. Philadelphia: Elsevier Saunders; 2012.Google Scholar
  29. 29.
    Gurgel CAS, Ramos EAG, Azevedo RA, Sarmento VA, da Silva Carvalho AM, dos Santos JN. Expression of Ki-67, p53 and p63 proteins in keratocyst odontogenic tumours: an immunohistochemical study. J Mol Histol. 2008;39:311–6.CrossRefPubMedGoogle Scholar
  30. 30.
    Henley J, Summerlin D-J, Tomich C, Zhang S, Cheng L. Molecular evidence supporting the neoplastic nature of odontogenic keratocyst: a laser capture microdissection study of 15 cases. Histopathology. 2005;47:582–6.CrossRefPubMedGoogle Scholar
  31. 31.
    John AM, Schwartz RA. Basal cell nevus syndrome: an update on Genetics and treatment. Br J Dermatol 2015; Sept. 26, Epub ahead of print.Google Scholar
  32. 32.
    Axelson M, Liu K, Jiang X, He K, Wang J, Zhao H, et al. U.S. Food and Drug Administration approval: vismodegib for recurrent, locally advanced, or metastatic basal cell carcinoma. Clin Cancer Res. 2013;19:2289–93.CrossRefPubMedGoogle Scholar
  33. 33.
    Tang JY, Mackay-Wiggan JM, Aszterbaum M, Yauch RL, Lindgren J, Chang K, et al. Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome. N Engl J Med. 2012;366:2180–8.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Atwood SX, Sarin KY, Whitson RJ, Li JR, Kim G, Rezaee M, et al. Smoothened Variants Explain the Majority of Drug Resistance in Basal Cell Carcinoma. Cancer Cell.; 2015;27:342–53.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  1. 1.Department of PathologyBrigham and Women’s HospitalBostonUSA
  2. 2.Harvard Medical SchoolBostonUSA
  3. 3.Department of Plastic and Oral SurgeryBoston Children’s HospitalBostonUSA
  4. 4.Harvard School of Dental MedicineBostonUSA

Personalised recommendations